Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels Effectiveness and Value

Tice Jeffrey A.; Kazi Dhruv S.; Pearson Steven D.

首页> 外文期刊>JAMA internal medicine >Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels Effectiveness and Value

【24h】

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels Effectiveness and Value

机译：前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型（PCSK9）抑制剂治疗高胆固醇水平的有效性和价值

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《JAMA internal medicine》 |2016年第1期|共2页
作者
Tice Jeffrey A.; Kazi Dhruv S.; Pearson Steven D.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels Effectiveness and Value [J] . Tice Jeffrey A., Kazi Dhruv S., Pearson Steven D. JAMA internal medicine . 2016,第1期

机译：前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型（PCSK9）抑制剂治疗高胆固醇水平的有效性和价值
2. Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels [J] . Michael T. Lipari, Wei Li, Paul Moran, The Journal of biological chemistry . 2012,第52期

机译：Furin-Creaved Proprotein转化酶枯草杆菌蛋白酶/ kexin型9（PCSK9）是活性的，并调节低密度脂蛋白受体和血清胆固醇水平
3. LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [J] . Sabatel-Perez F., Garcia-Ropero A., Santos-Gallego G., Drugs of today: Medicamentos de actualidad . 2019,第5期

机译：LDL胆固醇降低疗法：强调Proprotein转化酶枯草杆菌蛋白酶/ kexin型9（PCSK9）抑制剂
4. Towards Investigating the Role of Proprotein Convertase Subtilisin/Kexin Family (PCSK/7/9) in Cancer by Using Bioinformatics Motif Detection Technique [C] . Umar Draz, Sana Yasin, Shafiq Hussain, International Bhurban Conference on Applied Sciences and Technologies . 2021

机译：通过使用生物信息学主题检测技术来研究Proprotein转化酶枯草杆菌素/ kexin家族（PCSK / 7/9）的作用
5. Evaluation of the Interaction Between Proprotein Convertase Subtilisin/Kexin Type 9 and Sterol Carrier Protein-2 [D] . Ahranjani, Reza. 2017

机译：评价前蛋白转化酶枯草杆菌蛋白酶/ Kexin 9型与甾醇载体蛋白2的相互作用。
6. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER SPIRE and the Cholesterol Treatment Trialists Collaboration [O] . Brian A Ference, Christopher P Cannon, Ulf Landmesser, -1

机译：前蛋白转化酶枯草杆菌素-kexin 9型（PCSK9）抑制剂和他汀类药物可降低低密度脂蛋白胆固醇和心血管事件：FOURIERSPIRE和胆固醇治疗试验师合作的分析
7. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population [O] . Hitoshi Hamamura, Hisashi Adachi, Mika Enomoto, 2021

机译：血清ProProtein转化酶枯草杆菌素/ kexin型9（PCSK9）与胰岛素抵抗，甘油三酯，脂蛋白（A）水平独立相关，但在一般人群中不是低密度脂蛋白胆固醇水平

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels Effectiveness and Value

著录项

引文网络

相似文献

相关主题

期刊订阅